DAPT=dual antiplatelet therapy; HBR=high bleeding risk; 

*With Orsiro DES in comparison to Xience DES, based on Target Lesion Failure at 5-year follow-up Orsiro DES: 7.7% Xience DES: 11.1%  BIOSTEMI with historical information RR, 0.70; 95% BCI, 0.51-0.95, Bayesian posterior probability, 0.988 Difference: -31%. Clinical data collected with the Orsiro DES device within the Orsiro family clinical program. **Based on primary outcome in BIOFLOW-DAPT RCT including 1-month DAPT after PCI (Valgimigli M et al. Circulation 2023 Aug 25). Orsiro Mission DES is not indicated for one month of dual antiplatelet therapy (DAPT) in high bleeding risk (HBR) patients. Please refer to the IFU for indications and post-procedure antiplatelet therapy recommendations. ^∆ Posterior probability of superiority in STEMI in comparison to Xience at 24 months with respect to TLF, based on combined data set of BIOSTEMI and BIOSCIENCE STEMI groups.

1.BIOTRONIK data on file. Status February 2023; 2. Iglesias, JF. Long-Term Outcomes with Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With ST-Segment Elevation Myocardial Infarction: 5-Year Follow-up of the BIOSTEMI Randomized Trial, Presented at: TCT 2023; October 25, 2023; San Francisco, USA; 3. Valgimigli M. et al. Biodegradable-polymer or durable-polymer stents in patients at high bleeding risk: A randomized, open-label clinical trial, Circulation, 2023; 4. Valgimigli M. et al. Biodegradable-polymer or durable-polymer stents in patients at high bleeding risk: A randomized, open-label clinical trial, Circulation, 2023.

Clinical data collected with either Orsiro DES  or Orsiro Mission DES device within the Orsiro family clinical program.

Orsiro and Orsiro Mission are trademarks or registered trademarks of the BIOTRONIK Group of Companies. All other trademarks are the property of their respective owners.

© 2025 BIOTRONIK AG – All rights reserved.
Specifications are subject to modification, revision and improvement.